Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$22.82
-0.35-1.51%
At close: -
$22.82
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
AnaptysBio Analyst Ratings and Price Targets | NASDAQ:ANAB | Benzinga
AnaptysBio Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for AnaptysBio Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Guggenheim
Wedbush
JP Morgan
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for AnaptysBio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/04/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $22 → $38 | Upgrade | Neutral → Buy | Get Alert |
| 05/28/2025 | Buy Now | — | Guggenheim | Yatin Suneja55% | $54 → $90 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | — | Guggenheim | Yatin Suneja55% | $52 → $54 | Maintains | Buy | Get Alert |
| 05/01/2025 | Buy Now | — | Wedbush | Martin Fan 50% | $40 → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 03/05/2025 | Buy Now | — | JP Morgan | Anupam Rama59% | $36 → $42 | Maintains | Overweight | Get Alert |
| 03/04/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 02/13/2025 | Buy Now | — | Wells Fargo | Derek Archila58% | $40 → $51 | Maintains | Overweight | Get Alert |
| 02/12/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $19 → $22 | Maintains | Neutral | Get Alert |
| 02/07/2025 | Buy Now | — | Wedbush | David Nierengarten58% | $40 → $40 | Maintains | Outperform | Get Alert |
| 02/04/2025 | Buy Now | — | Wolfe Research | Andy Chen45% | — | Initiates | → Outperform | Get Alert |
| 02/04/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $19 → $19 | Reiterates | Neutral → Neutral | Get Alert |
| 12/19/2024 | Buy Now | — | JP Morgan | Anupam Rama59% | $66 → $36 | Maintains | Overweight | Get Alert |
| 12/18/2024 | Buy Now | — | Truist Securities | John Lee1% | $30 → $20 | Maintains | Hold | Get Alert |
| 12/12/2024 | Buy Now | — | Wells Fargo | Derek Archila58% | $56 → $40 | Maintains | Overweight | Get Alert |
| 12/12/2024 | Buy Now | — | Guggenheim | Yatin Suneja55% | $90 → $36 | Maintains | Buy | Get Alert |
| 12/11/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/02/2024 | Buy Now | — | BTIG | Julian Harrison37% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/12/2024 | Buy Now | — | JP Morgan | Anupam Rama59% | $75 → $66 | Maintains | Overweight | Get Alert |
| 11/06/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $55 → $52 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2024 | Buy Now | — | UBS | Eliana Merle48% | $23 → $33 | Maintains | Neutral | Get Alert |
| 10/21/2024 | Buy Now | — | Guggenheim | Yatin Suneja55% | $75 → $90 | Maintains | Buy | Get Alert |
| 09/26/2024 | Buy Now | — | Wedbush | David Nierengarten58% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | — | Truist Securities | John Lee1% | $20 → $30 | Maintains | Hold | Get Alert |
| 08/14/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | — | JP Morgan | Anupam Rama59% | $69 → $75 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | → $55 | Initiates | → Buy | Get Alert |
| 07/19/2024 | Buy Now | — | JP Morgan | Anupam Rama59% | $29 → $69 | Upgrade | Neutral → Overweight | Get Alert |
| 05/10/2024 | Buy Now | — | Wedbush | David Nierengarten58% | → $34 | Reiterates | Outperform → Outperform | Get Alert |
| 04/16/2024 | Buy Now | — | Leerink Partners | David Risinger72% | → $47 | Initiates | → Outperform | Get Alert |
| 04/11/2024 | Buy Now | — | Wells Fargo | Derek Archila58% | → $56 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | — | JP Morgan | Anupam Rama59% | $30 → $28 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | — | Wedbush | David Nierengarten58% | — | Upgrade | Neutral → Outperform | Get Alert |
| 02/26/2024 | Buy Now | — | BTIG | Julian Harrison37% | → $55 | Initiates | → Buy | Get Alert |
| 02/21/2024 | Buy Now | — | Stifel | Alex Schwartz43% | → $50 | Initiates | → Buy | Get Alert |
| 02/16/2024 | Buy Now | — | Piper Sandler | Yasmeen Rahimi60% | → $80 | Initiates | → Overweight | Get Alert |
| 11/29/2023 | Buy Now | — | Wedbush | David Nierengarten58% | → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 11/03/2023 | Buy Now | — | Wedbush | David Nierengarten58% | $18 → $20 | Maintains | Neutral | Get Alert |
| 11/02/2023 | Buy Now | — | UBS | Eliana Merle48% | $28 → $21 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | — | Wedbush | David Nierengarten58% | $29 → $26 | Maintains | Neutral | Get Alert |
| 05/22/2023 | Buy Now | — | JP Morgan | Anupam Rama59% | $31 → $30 | Upgrade | Underweight → Neutral | Get Alert |
| 05/12/2023 | Buy Now | — | Wedbush | David Nierengarten58% | → $29 | Reiterates | Neutral → Neutral | Get Alert |
| 05/12/2023 | Buy Now | — | Guggenheim | Yatin Suneja55% | $44 → $45 | Maintains | Buy | Get Alert |
| 04/12/2023 | Buy Now | — | JP Morgan | Anupam Rama59% | $32 → $31 | Maintains | Underweight | Get Alert |
| 01/06/2023 | Buy Now | — | Raymond James | Timur Ivannikov37% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/18/2022 | Buy Now | — | JP Morgan | Anupam Rama59% | $24 → $32 | Maintains | Underweight | Get Alert |
| 11/09/2022 | Buy Now | — | Raymond James | Steven Seedhouse35% | $30 → $38 | Maintains | Outperform | Get Alert |
| 11/01/2022 | Buy Now | — | Guggenheim | Yatin Suneja55% | — | Upgrade | Neutral → Buy | Get Alert |
| 09/19/2022 | Buy Now | — | HC Wainwright & Co. | Gobind Singh20% | → $35 | Assumes | → Buy | Get Alert |
| 09/13/2022 | Buy Now | — | Truist Securities | John Lee1% | $50 → $28 | Downgrade | Buy → Hold | Get Alert |
| 09/01/2022 | Buy Now | — | Raymond James | Steven Seedhouse35% | → $35 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for AnaptysBio (ANAB) stock?
The latest price target for AnaptysBio (NASDAQ:ANAB) was reported by HC Wainwright & Co. on June 4, 2025. The analyst firm set a price target for $38.00 expecting ANAB to rise to within 12 months (a possible 66.52% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AnaptysBio (ANAB)?
The latest analyst rating for AnaptysBio (NASDAQ:ANAB) was provided by HC Wainwright & Co., and AnaptysBio upgraded their buy rating.
When was the last upgrade for AnaptysBio (ANAB)?
The last upgrade for AnaptysBio Inc happened on June 4, 2025 when HC Wainwright & Co. raised their price target to $38. HC Wainwright & Co. previously had a neutral for AnaptysBio Inc.
When was the last downgrade for AnaptysBio (ANAB)?
The last downgrade for AnaptysBio Inc happened on December 11, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for AnaptysBio Inc.
When is the next analyst rating going to be posted or updated for AnaptysBio (ANAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AnaptysBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AnaptysBio was filed on June 4, 2025 so you should expect the next rating to be made available sometime around June 4, 2026.
Is the Analyst Rating AnaptysBio (ANAB) correct?
While ratings are subjective and will change, the latest AnaptysBio (ANAB) rating was a upgraded with a price target of $22.00 to $38.00. The current price AnaptysBio (ANAB) is trading at is $22.82, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
